Drugs / Enstilar
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ENSTILAR | — | 2015-10-16 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT06329258 | Dec 2022 → Nov 2023 | psoriasis | Psoriasis Treatment Center of Central New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT05185258 | Feb 2022 → Jan 2024 overdue | psoriasis | Aarhus University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03441789 | Sep 2017 → Oct 2018 | psoriasis | L.H. Kircik, M.D. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03731091 Comparator | Oct 2018 → Mar 2020 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enstilar | “one target lesion (plaque # 1) will be actively treated with once-daily cutaneous application of Enstilar® foam” NCT05185258 ↗ |
| Route | Topical | “Enstilar foam applied to affected areas daily” NCT03441789 ↗ |